Synapse - Works

Results (22056)

Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial

Meeting Abstract

Michel, L.; Jimeno, A.; Sukari, A.; Beck, T.; Chiu, J. W. Y.; Ahern, E. S.; Hilton, J.; Hollebecque, A.; Zanetta, S.; Patel, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)

Meeting Abstract

Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Combined patient specific tumor and HPV sequencing enables high sensitivity detection of ctDNA in HPV-associated oropharyngeal carcinoma patients

Meeting Abstract

Diplas, B. H.; Brown, D.; Pei, X.; Graybill, C.; Novaj, A.; Korn, W. M.; Daber, R.; Humm, J.; Shukla-Dave, A.; Schoder, H.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

Meeting Abstract

O'Cearbhaill, R. E.; Moore, K. N.; Yeku, O.; Liu, J. F.; Bouberhan, S.; Hamilton, E. P.; Hou, J. Y.; Van Nieuwenhuysen, E.; Papadimitriou, K.; Yoo, S. Y.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/ KEYNOTE-775

Meeting Abstract

Colomba, E.; Lorusso, D.; Mackay, H.; Moore, R.; Yonemori, K.; Kim, Y. M.; Sanli, U. A.; Xie, R.; Barresi, G.; McKenzie, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

Meeting Abstract

Dagogo-Jack, I.; Dowlati, A.; Guo, R.; Awad, M. M.; Swalduz, A.; Calvo, E.; Garcia, V. M.; Adjei, A. A.; Lorusso, P.; Punekar, S.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer

Meeting Abstract

Drilon, A.; Shen, L.; van Tilburg, C.; Doz, F.; Tan, D. S. W.; Lin, J. J.; Kummar, S.; Lassen, U. N.; McDermott, R. S.; Dierselhuis, M. P.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA)

Meeting Abstract

Drilon, A.; Rivera, I. I. R.; Spira, A. I.; Sharma, M. R.; Hansen, R.; Chowdhry, S.; Kasibhatla, S.; Tewari, A.; Weymer, S.; Wagner, K.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

Meeting Abstract

Schoeffski, P.; Lorusso, P.; Yamamoto, N.; Lugowska, I.; Garcia, V. M.; Lauer, U.; Hu, C.; Jayadeva, G.; Lahmar, M.; Gounder, M.
Annals of Oncology (2023)

Fulltext@MSK | Save

Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia

Meeting Abstract

DeMatteo, R.; Sgroe, E.; Merrill, M. B.; Gounder, M.; Liu, D.
Annals of Oncology (2023)

Fulltext@MSK | Save